大剂量化疗联合自体造血干细胞移植治疗淋巴瘤的临床疗效观察

doi:10.12092/j.issn.1009-2501.2018.12.014

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (12): 1397-1401.doi: 10.12092/j.issn.1009-2501.2018.12.014

大剂量化疗联合自体造血干细胞移植治疗淋巴瘤的临床疗效观察

封媛媛，丁凯阳，王翠翠

中国科学技术大学附属第一医院西区（安徽省肿瘤医院）血液科，合肥 230000，安徽

收稿日期:2018-07-26 修回日期:2018-08-21 出版日期:2018-12-26 发布日期:2018-12-27
通讯作者: 丁凯阳，男，博士，主任医师，主要从事恶性血液病的临床与基础研究。 Tel：0551-65897860 E-mail：dingkaiy@126.com
作者简介:封媛媛，女，硕士，医师，主要从事淋巴瘤与骨髓瘤的临床研究。
基金资助:
安徽省科技厅重点研究与开发项目（1804h08020249）

Clinical observation of 40 patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation

FENG Yuanyuan, DING Kaiyang, WANG Cuicui

Department of Hematology, the West Part of the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital) , Hefei 230000, Anhui, China

Received:2018-07-26 Revised:2018-08-21 Online:2018-12-26 Published:2018-12-27

摘要/Abstract

摘要：

目的: 观察大剂量化疗联合自体造血干细胞移植（AHSCT）对于淋巴瘤的临床疗效。方法: 以2013年3月至2018年2月在安徽省肿瘤医院行AHSCT的40例恶性淋巴瘤患者为研究对象，4例霍奇金淋巴瘤（Hodgkin's lymphoma，HL）,36例非霍奇金淋巴瘤（non-Hodgkin's lymphoma，NHL）。采用依托泊苷+G-CSF为外周血干细胞动员方案。预处理方案为BEAM、CBV及BEAC方案。结果: 40例患者外周血干细胞采集数量均足够，未出现移植相关死亡。中性粒细胞和血小板植入时间的中位数分别为10 d（7~17 d）和12 d（6~25 d）。随访时间中位数是15个月（1~53个月），无进展生存（PFS）率为72.5%，总生存（OS）率为（82.5%）。移植前达完全缓解（CR）的AHSCT患者预后良好；国际预后指数（IPI）评分大于2分的AHSCT患者预后不良。结论: AHSCT对改善恶性淋巴瘤患者的预后有显著的意义。

关键词: 淋巴瘤, 造血干细胞移植, 自体造血干细胞移植

Abstract:

AIM: To investigate the therapeutic effect of the patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT)．METHODS: The follow up data in 40 patients with malignant lymphoma who recieved AHSCT in Anhui Province Cancer Hospital from March 2013 to February 2018 were analyzed retrospectively．Of the 40 patients, 4 were Hodgkin's lymphoma (HL) and 36 were non-Hodgkin's lymphoma (NHL). To mobilize peripheral hematopoietic stem cell, etoposide combined with G-CSF was used. Preconditioning regimens included BEAM, CBV and BEAC. RESULTS:All patients were collected enough peripheral blood stem cells．None of the patients were died for the risks of AHSCT. The median time of the absolute neutrophil count (ANC) implanted was 10 (7-17) days．And the median time of platelet count implanted was 12 (6-25) days．The median survival time was 15 (1-53) months, progression free survival (PFS) was 72.5%，and overall survival (OS) was 82.5%.The patients who achieved CR status before transplantation could have a favorable prognosis. The prognosis in the patients with IPI score>2 was poor.CONCLUSION:AHSCT can improve the prognosis of patients with malignat lymphoma.

Key words: lymphoma, autologous hematopoietic stem cell transplantation, hematopoietic stem cell transplantation

中图分类号:

R733
R552

封媛媛，丁凯阳，王翠翠. 大剂量化疗联合自体造血干细胞移植治疗淋巴瘤的临床疗效观察[J]. 中国临床药理学与治疗学, 2018, 23(12): 1397-1401.

FENG Yuanyuan, DING Kaiyang, WANG Cuicui. Clinical observation of 40 patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1397-1401.

参考文献

［1］Stiff PJ,Unger JM,Cook JR,et al.Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma［J］.N Engl J Med,2013,369(18):1681-1690．
［2］Nagle SJ,Woo K,Schuster SJ,et al.Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era［J］.Am J Hematol,2013,88(10):890-894.
［3］赵瑾,苏丽萍,王晶荣,等.自体造血干细胞移植治疗恶性淋巴瘤效果观察［J］.淋巴瘤·白血病,2015,24(11):679-681.
［4］Grawohl A, Hermans J, Baldomero H. Blood and marraw transplantation activity in Europe 1995［J］. Bone Marrow Transplant, 1997, 19:407-419.
［5］Philip T,Guglielmi C,Hagenbeek A,et al.Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma［J］.N Engl J Med,1995,333(23):1540-1545.
［6］Czyz A,Lojko-Dankowska A,Dytfeld D,et al.Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma:a single-center experience［J］.Med Oncol,2013,30(3):611.
［7］马军，邱录贵．应重视造血干细胞移植在淋巴瘤治疗中的应用与推广［J］.中华血液学杂志,2014,35(4):273-274．
［8］Zelenetz Ad,Gordon LI,Wierda WG,et al.Non-Hodgkin's lymphomas,version 2.2014［J］.J Natl Compr Canc Netw,2014,12(6):916-946.
［9］Yin J，Wei J, Xu JH, et al.Autologous stem cell transplantation asthe first-line treatment for peripheral T cell lymphoma:results of a comprehensive meta-analysis［J］.Acta Haematol,2014,131（2）:114-125.
［10］Yoon JH, Kim JW, Jeon YW, et al. Role of frontline autologous stem cell transplantation in young,high-risk diffuse large B-cell lymphoma patients［J］.Korean J Intern Med, 2015, 30（3）:362-371.
［11］Smith SD, Bolwell BJ, Rybicki LA, et al. Comparison of outcomes after auto-SCT for patients with relapsed diffuse largeB-cell lmphoma according to previous therapy with rituximab［J］.Bone Marrow Transplant,2011,46(2):262-266.
［12］Williams ME,Densmore JJ.Biology and therapy of mantle cell lymphoma［J］.Curr Opin Oncol,2005,17(5):425-431.
［13］Lacasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database［J］.Blood,2012,119(9):2093-2099.
［14］Gui L, Shi YK, He XH, et a1.High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis［J］. Int J Hematol,2014,99(1):69-78．
［15］Shin HJ, Lee WS, Lee HS, et al.Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma［J］.Leuk Lymphoma,2014,55(11):2490-2496．
［16］William BM, Loberiza FR, Whalen V, et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma［J］.Clin Lymphoma Myeloma Leuk,2013,13(4):417-423．
［17］蒲欣,陈洁平.自体造血干细胞移植治疗高危难治淋巴瘤生存分析［J］.重庆医学，2016，45(12)：1620-1623.
［18］王莉,范磊，徐卫，等.自体造血干细胞移植治疗81例恶性淋巴瘤患者临床分析［J］．中华血液学杂志，2014，35(4)：328-331．

[1]	王甜甜, 曹俊杰, 刘旭辉, 裴仁治, 陆滢. 氟达拉滨联合后置环磷酰胺用于单倍体造血干细胞移植临床疗效分析[J]. 中国临床药理学与治疗学, 2022, 27(3): 295-301.
[2]	李雯霞, 方柳圆, 钱申贤. 铁死亡的机制及其在淋巴瘤中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 314-321.
[3]	彭敏, 黄攀豪, 邓银华, 刘文, 李威, 于珍, 夏青, 谢悦良. 造血干细胞移植患者伏立康唑稳态谷浓度监测及其影响因素分析[J]. 中国临床药理学与治疗学, 2021, 26(6): 640-646.
[4]	娄安琦, 余俊先, 程子昭, 苏强. 布鲁顿氏酪氨酸激酶（BTK）抑制剂与难治性套细胞淋巴瘤[J]. 中国临床药理学与治疗学, 2021, 26(6): 680-686.
[5]	潘战和, 王馨, 苏安, 张鹏, 纪浩南, 王小梅. 基于Notch 1/NF-κB/STAT3通路探讨塞来昔布逆转NK/T细胞淋巴瘤细胞阿霉素耐药的作用机制[J]. 中国临床药理学与治疗学, 2020, 25(12): 1330-1336.
[6]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[7]	陈冰, 张帆, 卢林明, 朱晓群, 刘银华, 何雷. 中国皖南地区728例恶性淋巴瘤的构成分析[J]. 中国临床药理学与治疗学, 2013, 18(4): 388-393.
[8]	陈均法, 郑智茵, 沈建平, 沈一平, 周郁鸿. Hyper-CVAD/MA+G-CSF对淋巴瘤患者造血干细胞动员作用的研究[J]. 中国临床药理学与治疗学, 2010, 15(12): 1410-1413.
[9]	吉兆宁, 刘国卿, 许多荣, 洪文德. 非何杰金氏淋巴瘤 P16 基因纯合性缺失及其临床意义[J]. 中国临床药理学与治疗学, 2002, 7(1): 60-62.
[10]	张国英, 王振怀, 宋延礼, 高绪田, 綦玉珍. γ-干扰素联合化疗治疗非霍奇金淋巴瘤50 例[J]. 中国临床药理学与治疗学, 2001, 6(3): 239-240.

大剂量化疗联合自体造血干细胞移植治疗淋巴瘤的临床疗效观察

Clinical observation of 40 patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价